Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294304 · ClinicalTrials.gov registry record · Phase 2
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
A Phase 2 study of Muscle-invasive Bladder Cancer, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT03294304 is a Phase 2 study of Muscle-invasive Bladder Cancer that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 43 participants, below the 1,331-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03294304, a Phase 2 study of Muscle-invasive Bladder Cancer, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients will receive neoadjuvant treatment with nivolumab in combination with gemcitabine-cisplatin (GC) every 3 weeks for 4 treatment cycles over 12 weeks followed by standard of care radical cystectomy.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Gemcitabine
Study Locations (3)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Masonic Cancer Center - University of Minnesota - Minneapolis
Utah
- Huntsman Cancer Institute - University of Utah Health - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294304
The ClinicalTrials.gov registry entry for NCT03294304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,331-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle-invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT03294304 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Minnesota, Utah.
Frequently Asked Questions
What is clinical trial NCT03294304 about?
NCT03294304 is a clinical study titled "BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy". This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients will receive neoadju...
What is the current status of trial NCT03294304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-01-29. Estimated completion is 2021-07-01.
What conditions does trial NCT03294304 study?
This clinical trial studies the following conditions: Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT03294304?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03294304?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03294304 being conducted?
This trial has 3 study locations across Massachusetts, Minnesota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
COMPLETED · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
-
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
RECRUITING · NA
-
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
ACTIVE NOT RECRUITING · Phase 3
-
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.